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Abstract
Background: Fibrinolytic therapy is the main reperfusion therapy for most STEMI patients in several countries. Current
practice guidelines recommended routine early pharmacoinvasive (within 3–24 h after successful fibrinolysis, however
it cannot be performed in timely fashion due to limitation of PCI-capable hospitals. This study aimed to evaluate the
prognostic utility of the GRACE score in patients receiving delayed intervention after successful fibrinolysis in non
PCI-capable hospital.
Methods: We retrospectively analysed the data from the Maharaj Nakorn Chiang Mai Hospital acute ST-elevation
myocardial infarction (STEMI) registry during the period 2007–2012. The STEMI patients who had successfully fibrionolysis
in non PCI-capable hospital and received delayed PCI (during 24 h to 14 days after successful fibrinolytic therapy) at
Maharaj Nakorn Chiang Mai hospital were included. The primary end point for this analysis was the composite
outcomes, which included all-cause mortality, re-hospitalization with acute coronary syndrome (ACS), re-hospitalization
with heart failure (HF) and stroke at 1 and 6-month.
Results: A total of 152 patients were included. 88 patients and 64 patients were in low GRACE group (GRACE risk
score≤ 125) and intermediate to high GRACE group (GRACE risk score above 126), respectively. The median time from
fibrinolysis to coronary intervention in low GRACE group was 8.5 days (interquartile range, 4.6–10.9) and 7.9 days
(interquartile range,3.2,12.0) in intermediate to high GRACE group (p = 0.482). At 1 month, the composite cardiovascular
outcome at 1 month occurred in 2 patients (2.3 %) in low GRACE group and 10 patients (15.6 %) in intermediate to high
GRACE group (P = 0.003). During 6 months, the composite cardiovascular outcomes occurred in 6 patients (6.8 %) in low
GRACE group and 12 patients (18.7 %) in intermediate to high GRACE group (P = 0.024). The cumulative of composite
cardiovascular outcome was significant higher in intermediate to high GRACE group than in low GRACE group (Hazard
ratio: 2.97, 95 % CI 1.11–7.90; p = 0.030).
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Conclusion: The long delay pharmacoinvasive strategy in intermediate to high GRACE score after successful fibrinolysis
in non PCI-capable facilities were associated with worse cardiovascular outcomes than the patients with low GRACE
score at 1 and 6 months. GRACE risk score may be helpful and guided the clinicians in non PCI-capable center in early
transferred to early intervention in STEMI patients after fibrinolytic therapy.
Keywords: GRACE risk score, STEMI patients with successfully fibrinolysis, Delay pharmacoinvasive strategy
Background
Primary percutaneous coronary intervention (PPCI) is
preferred reperfusion therapy for acute ST-elevation
myocardial infarction (STEMI). However, the PCI-capable
center is still limited in several countries including
Thailand. Therefore, fibrinolytic therapy is the main reper-
fusion therapy for most STEMI patients in our country.
Current practice guidelines recommended routine coronary
angiogram (CAG) after successful fibrinolysis, the so called
pharmacoinvasive strategy [1–5]. However, early pharma-
coinvasive (within 3–24 h after successful fibrinolysis) can-
not be performed in a timely fashion due to limitation of
PCI-capable hospitals. Previous acute coronary syndrome
(ACS) registries, Thailand Registry in Acute Coronary
Syndrome (TRACS) showed a low rate of coronary angiog-
raphy and intervention during index admission and referral
centers for early pharmacoinvasive strategy are still limited
[6]. Therefore, risk stratification and identify risk of the
patients are important in non PCI-capable hospital. Patients
with intermediate to high risk for adverse cardiovascular
event should be transferred for coronary angiogram as soon
as possible. Although several risk scores for acute coronary
syndrome (ACS) have been developed for stratified risk of
ACS patients, GRACE (Global Registry of Acute Coronary
Events) score is developed to focus on clinical risk assess-
ment and to improve the selection of patients for clinical
and interventional procedures following an ACS episode
[7]. Many studies and meta-analysis demonstrated the
accuracy and the usefulness of the GRACE score on the
mortality of ACS patients in hospital and follow-up after
hospital discharged [8–13]. This study aimed to evaluate
the prognostic utility of the GRACE score in patients
receiving delayed intervention after successful fibrinolysis.
Methods
Study design and population
We retrospectively analysed the data from the Maharaj
Nakorn Chiang Mai Hospital STEMI registry during the
period 2007–2012. The STEMI patients who had
successfully fibrinolysis in non PCI-capable hospital and
received delayed coronary intervention (during 24 h to
14 days after successful fibrinolytic therapy) at Maharaj
Nakorn Chiang Mai hospital were included for analysis
in the study. The exclusion criteria were the patients
who unsuccessfully fibrinolysis (ST-segment decrease in
elevation less than 50 % at 90 min after fibrinolysis),
received early coronary intervention (<24 h after
fibrinolytic therapy), received very delayed coronary
intervention (>2 weeks after fibrinolytic therapy), the
patients who denied for further interventions after
fibrinolysis, the patients who received primary PCI or
rescue PCI and the patients who had the previous
history of coronary-artery bypass surgery. The protocol
design was approved by the local institutional Research
Ethics Committees of Faculty of Medicine, Chiang Mai
University and Lampang hospital.
The data were collected from the medical recorded by
the researcher. Demographic characteristics, medical
history, presenting symptoms, baseline GRACE score
time from symptom onset to administration fibrinolytic
therapy, time from fibrinolysis to percutaneous coronary
intervention, coronary intervention procedure and
clinical outcomes were collected for analysis. In the
patients who did not visit to the hospital to follow up,
the telephone call was used to interview for evaluating
the clinical outcomes.
Definitions and end points
The STEMI was defined as the presence of at least
0.1-mV ST-segment elevation or new or presumably
new left bundle branch block with elevation of cardiac
enzyme levels above the reference range. Successfully
fibrinolysis means the ST-segment decrease in eleva-
tion ≥ 50 % (partial resolution) and ≥ 70 % (complete
resolution) at 90 min after fibrinolysis. Delayed coronary
intervention means coronary intervention, including
coronary angiogram and percutaneous coronary in-
tervention performed during 24 h to 14 days after
successfully fibrinolysis. The GRACE score composed of
medical history (age, history of congestive heart failure,
and history of myocardial infarction), findings at initial
presentation (resting heart rate, systolic blood pressure,
and ST-segment depression), and findings during
hospitalization (initial serum creatinine, elevation of
cardiac enzyme, and no in-hospital PCI), the total score
range from 0–258 points. The patients were stratified
into low (GRACE risk score <126), intermediate to high
risk group (GRACE risk score ≥126). The primary end
point for this analysis was composite outcomes, which
included all-cause mortality, re-hospitalization with
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ACS, re-hospitalization with heart failure (HF) and
stroke at 1 and 6-month. Re-hospitalized with ACS was
defined as re-admission after discharge from hospital
with ACS composed with clinical chest pain, rising of
cardiac enzymes and dynamic ST-segment change.
Re-hospitalized with heart failure was defined as re--
admission after discharge from hospital with clinical de-
compensated heart failure or received intravenous
diuretic. Culprit vessel PCI was defined as PCI confined to
culprit vessel lesion only. The multivessel PCI was defined
as PCI in which lesions in the culprit vessel as well as ≥1
non-culprit vessel lesions.
Statistical analysis
Baseline demographics, procedural and angiographic
characteristics presented with continuous measures and
are expressed as mean ± standard deviation (SD) or me-
dian and interquartile range (IQR) wherever appropriate.
The categorical data are expressed as number (percent-
ages), except where indicated. Differences in continuous
variables were analyzed with the Student’s t test or
Wilcoxon rank-sum tests. The categorical variables were
analyzed with Chi-square test and Fisher’s exact test. A
P-value <0.05 was considered statistically significant.
Composite endpoints and other clinical outcomes will
be expressed as number (percentages). The prognostic
utility of GRACE score on clinical outcomes was
analyzed by logistic regression analysis and presented as
odd ratio and area under the ROC curve (AuROC). The
composite outcome was analyzed by use time to event
analysis and presented with Kaplan-Meier curve. We
conducted statistical analyses using Stata version 13
(Stata corporation, College Station, TX). The sample size
was calculated by base on the data of the previous study
of Yan et al. [14] reported death/myocardial re-infarction
at 30 days in the standard treatment was 8.1 % and
estimated 5 % loss of follow-up. To achieve a power of
80 %, with a type-1 error probability of 5 % (two-sided),
allowable of estimated error (margin error) was 5 %, 120
patients were needed in this study.
Results
Baseline clinical characteristics
Among 3171 STEMI patients during study period, 2045
STEMI patients received fibrinolytic therapy and a total
of 152 patients met inclusion criteria, as shown in Fig. 1.
Eighty-eight patients and 64 patients were in low
GRACE group (GRACE risk score ≤ 125) and intermedi-
ate to high GRACE group (GRACE risk score above
126), respectively. The 6-month follow-up was available
in 97 % of the patients in both groups. The clinical
characteristics were shown in Table 1. The median time
from fibrinolysis to coronary intervention in low GRACE
group was 8.5 days (interquartile range, 4.6–10.9) and
7.9 days (interquartile range,3.2,12.0) in intermediate to
high GRACE group (p = 0.482) (Additional file 1).
Angiographic findings, procedural details and
complications of the procedure
Angiographic findings and procedural details were
presented in Table 2. Double vessel disease and triple
vessel disease presented in 45.5 and 65.6 % in low
GRACE group and intermediate to high GRACE group
respectively. Lesion type B2 and C presented in 44.6 and
53.8 % in low GRACE group and intermediate to high
GRACE group respectively. Sixty-three percent (N = 56)
of the patients in low GRACE group and 61 % (N = 39)
of the patients in intermediate to high GRACE group
underwent PCI (P =0.738) while 36 % of the patients in
low GRACE group (N = 32) and 39 % of the patients in
intermediate to high GRACE group (N = 25) had only
coronary angiography (p = 0.738). Culprit vessel PCI was
performed in 89 % (N = 50) of the patients in low
GRACE group and 92 % (N = 36) of the patients in
intermediate to high GRACE group (=0.733). Among
the patients underwent PCI, 76.8 % (N = 43) of the
patients in low GRACE group and 76.3 % (N = 29) of the
patients in intermediate to high GRACE group received
drug-eluting stent (DES). The complications during and
post procedure were shown in Table 3.
Clinical outcomes
At 1 month, the composite cardiovascular outcome at
1 month occurred in 2 patients (2.3 %) in low GRACE
group and 10 patients (15.6 %) in intermediate to high
GRACE group (P = 0.003). During 6 months, the com-
posite cardiovascular outcomes occurred in 6 patients
(6.8 %) in low GRACE group and 12 patients (18.7 %) in
intermediate to high GRACE group (p = 0.024) (Table 4).
There was no death in hospital in low GRACE group
when 2 patients (3.1 %) in intermediate to high GRACE
group died (P = 0.176). Rate of re-hospitalized with HF
at 1 and 6 months were significantly higher in inter-
mediate to high GRACE group than low GRACE group
(9.4 % vs 1.1 %, p = 0.022 and 10.9 % vs 2.3 %, p = 0.036,
respectively).
The GRACE score and clinical outcomes
The composite cardiovascular outcome and re-hospitalized
with HF at 6 months were higher in intermediate to high
GRACE group than in the low GRACE group (OR: 3.20,
95 % CI: 1.13–9.06; P = 0.029 and OR: 5.34, 95 % CI:
1.07–26.68; P = 0.041 respectively). The cumulative of
composite cardiovascular outcome was significant higher in
intermediate to high GRACE group than in low GRACE
group (Hazard ratio: 2.97, 95 % CI 1.11–7.90; P = 0.030), as
shown in Fig. 2. We analysed the prognostic utility of
GRACE score on clinical outcomes by the evidence from
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the area under the ROC curve. The area under the ROC
(AuROC) of GRACE score for 6-month cardiovascular
death was 0.794 (95 % CI 0.75–0.83). The AuROC of
composite cardiovascular outcomes was 0.641 (95 % CI
0.52–0.76), as shown in Fig. 3.
Discussion
Although early pharmacoinvasive strategy (within
3–24 h) after successful reperfusion are recommended
by several guidelines [1–5], timely fashion CAG is not
widely available in countries with limited PCI capable
hospitals including Thailand. Several randomized trials
and meta-analysis have shown that early routine post-
thrombolysis angiography with subsequent PCI reduced
the rates of re-infarction and recurrent ischemia
compared with a watchful waiting strategy, in which
angiography and revascularization were indicated only in
the patients with spontaneous or induced severe
ischemia or left ventricular (LV) dysfunction [15, 16].
The benefits of early routine PCI after thrombolysis
were seen in the absence of increased risk of adverse
events in many studies [15, 16]. The data from TRACS
showed only half (50 %) of STEMI patients performed
CAG on index admission. Fibrinolysis (especially
streptokinase), is the first choice for treatment in low
risk STEMI patients (42.6 % of STEMI patients received
streptokinase and 1 % received Tenecteptase) [6].
Because of only one cardiac catheterization (during the
period 2007–2012) in Northern Thailand (Maharaj
Nakorn Chiang Mai Catheterization laboratory), the
3,171 STEMI patients
(Non PCI-capable hospital)
2,917 STEMI patients may be 
candidate for thrombolytic
Transfer to Primary PCI 
(254 patients)
2,045 patients received 
thrombolytic (streptokinase)









Refuse CAG or PCI (418 patients)
Non-invasive strategy (ischemia-guided) (522 patients)
215 patients received long delay 
pharmacoinvasive (24 hours to 2 weeks)
Very long delay (> 2weeks) (465 patients)
Early pharmacoinvasive (   24 hours) (123 patients)
152 patients were included in 
analysis
Incomplete data for analysis i.e. ECG (63 patients)
Fig. 1 Study flow chart
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geographic and long distance of transfer and few of
number of interventional cardiologists, primary PCI and
early routine PCI after successful fibrinolysis were very
difficult for this situation. Rescue PCI or primary PCI
were performed in the patients who failed fibrinolytic
therapy or cardiogenic shock at presentation. Hence,
most of the STEMI patients in Thailand, especially in
Northern of Thailand who successfully fibrinolytic
therapy received the long delay coronary intervention
(more than 24 h after fibrinolysis) and some of them
received elective PCI or very long delayed intervention
or elective PCI (after 2 weeks from successful fibrinolytic
therapy) [6]. Several studies demonstrated the worst car-
diovascular outcomes in the patients who received delay
coronary intervention after thrombolysis [15–21]. The
Southwest German Interventional Study in Acute
Myocardial infarction (SIAM III) evaluated the effects of
transfer early PCI (within 6 h after fibrinolysis) com-
pared with delay PCI strategy (elective PCI 2 weeks after
fibrinolysis) [17]. The early PCI showed significant
reduction of primary end point (death, re-infarction,
target lesion revascularization (TLR) and ischemic
events) (HR: 0.61; 95 % CI 0.42–0.88, p = 0.008) and
higher long term survival than delayed PCI (p = 0.057)
[17]. Similarly to The Trial of Routine Angioplasty and
Stenting after Fibrinolysis to Enhance Reperfusion in
Acute Myocardial Infarction (TRANSFER-AMI) trial,
showed that the patients who transfer from non-PCI
Table 1 Baseline clinical characteristics of patients according to
GRACE risk score (n = 152)
Clinical characteristics Low GRACE
group (N = 88)
Intermediate
to high GRACE
group (N = 64)
P-value
Age (years), mean ± SD 55.3 ± 8.5 67.7 ± 3.2 < 0.001
Gender, (%) 0.696
Male 55(62.5) 38(59.4)





2.7 (IQR: 2,3.8) 2.8 (IQR: 2,4.5) 0.347
Time from fibrinolysis to
CAG or PCI median (days)
(IQR:25th,75th percentile)
8.5 (IQR:4.6,10.9) 7.9 (IQR: 3.2,12.0) 0.482
GRACE score, mean ± SD 100.2 ± 15.7 142.2 ± 13.4 < 0.001
LVEF (%) 54.9 ± 10.6 52.5 ± 13.6 0.239
Preexisting medical conditions, n (%)
Diabetes 18 (20.4) 10.6 (15.6) 0.448
Hypertension 39 (44.3) 27 (42.2) 0.794
Dyslipidemia 30 (34.1) 16 (25.0) 0.228
Smoking 50 (56.8) 34 (53.1) 0.651
Chronic kidney disease 3 (3.4) 3 (4.7) 0.681




group (N = 88)
Intermediate to high
GRACE group (N = 64)
P-value
Angiographic findings, n (%)
Mild disease 9 (10.2) 1 (1.6) 0.045
Single vessel disease 39 (44.3) 21 (32.8) 0.180
Double vessel disease 24 (27.3) 22 (34.4) 0.375
Triple vessel disease 16 (18.2) 20 (31.2) 0.082
Lesions (according to ACC/AHA), n (%)
Type A 14 (25.0) 7 (18.0) 0.461
Type B1 17 (30.4) 11 (28.2) 0.503
Type B2 17 (30.4) 10 (25.6) 0.651




32 (36.4) 25 (39.1) 0.738
Medical treatment 26 (81.2) 15 (60.0) 0.136
CABG 6 (18.8) 10 (40.0) 0.136
PCI, n (%) 56 (63.6) 39 (60.9) 0.738
Culprit vessel PCI 50 (89.3) 36 (92.3) 0.733
Multivessel PCI 6 (10.7) 3 (7.7) 0.733
Procedural details, n (%)
POBA 1 (1.8) 6 (15.4) 0.018
Thrombus aspiration 0 (0) 3 (7.7) 0.066
Bare metal stent 13 (23.2) 5 (13.2) 0.290
Drug eluting stent 43 (76.8) 29 (76.3) 0.574
Table 3 Complications during and post-procedure (n = 152)
Complications Low GRACE
group (N = 88)
Intermediate to high
GRACE group (N= 64)
P-value
During procedure, n (%)
Abrupt vessel closure 0 (0) 0 (0) NS
New thrombus
formation
2 (3.57) 0 (0) 0.511
Side branch occlusion 0 (0) 0 (0) NS
No reflow 2 (3.57) 0 (0) 0.511
Dissection 1 (1.8) 0 (0) 0.589
Emergency unplanned
CABG
0 (0) 0 (0) NS
Post procedure, n (%)
Hematoma 0 (0) 0 (0) NS
Hematuria 1 (1.1) 0 (0) 0.579
Gastrointestinal
bleeding
0 (0) 0 (0) NS
Required blood
transfusion
0 (0) 0 (0) NS
Contrast-induced
nephropathy
0 (0) 0 (0) NS
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center within 6 h after thrombolysis had fewer ischemic
complications than standard treatment (delayed PCI)
without increasing of major bleeding [18]. A meta-
analysis showed mortality benefit at 30-day and 1 year of
the STEMI patients with early transfer PCI after
fibrinolysis as compared with ischemic-guided interven-
tion (delayed PCI) [15, 16]. The NORwegian study on
District treatment of ST-Elevation Myocardial infarction
(NORDISTEMI) study also demonstrated a significant
reduction in the composite cardiovascular outcome
(death, re-infarction, stroke, or recurrent ischemia) at
1 year in the patients with immediate transferred to PCI
following with thrombolysis as compared with the
patients in conservative arm treatment (6 % vs 16 %, p =
0.01) [19]. Similarly to The Combined Abciximab RE-te-
plase Stent Study in Acute Myocardial Infarction (CA-
RESS-AMI) study, a more conservative strategy (i.e.
angiogram only in cases of failed thrombolysis) was
associated with a worse clinical outcome than the
strategy of angiogram and intervention (if indicated) in
all cases following thrombolysis (composite of death,
re-infarction and refractory ischemia at 30-day, 11 % vs
4 %, p = 0.004) [20]. From the previous data, no studies
demonstrated of the benefit in the cardiovascular
outcomes of the early and/or delay pharmacoinvasive
strategies in STEMI patients who received streptokinase
for treatment similar to our study. On the data from
CARESS-AMI [20] and TRANSFER-AMI [18], The
American College of Cardiology (ACC) and the
American heart association (AHA) give a class IIa
recommendations for high risk features (such as Kilip
class >2, extensive ST-elevation, left ventricular ejection
fraction (LVEF) <35 %, or hypotension) should be imme-
diate transferred to PCI-capable facilities [3, 4]. The
transfer of low and moderate risk STEMI patients to
PCI-capable center received a class IIb recommendation.
No available data showed the benefit outcome of early
transferred for PCI in low and moderate risk patients.
Risk stratification of the STEMI patients were very
important for the clinicians in non-PCI capable hospital to
use to guide for judged and selected the STEMI patients
for early invasive strategy. GRACE risk score, one of clinical
risk score, has been shown to be a good risk stratification
score in population with STEMI and NSTE-ACS. Several
studies demonstrated the validation and the usefulness of
GRACE score in stratified the STEMI patients for an early
invasive management (AUC= 0.81; 95 % CI 0.80–0.82 for
STEMI and AUC= 0.80; 95 % CI 0.74–0.89 for NSTE-
ACS) [12]. The AuROC of 6-month mortality and the
composite cardiovascular outcome of our study were 0.794
(95 % CI 0.75–0.83) and 0.641 (95 % CI 0.52–0.76). From
our study, the GRACE score seem to be better performance
in the cardiovascular mortality rather than the composite
cardiovascular outcome of the patients with long delay
pharmacoinvasive as similar as the previous study [12]. But
the usefulness of GRACE score for predict the composite
cardiovascular outcome is still unclear. A subgroup analysis
of TRANSFER-AMI trial revealed the beneficial outcome
of early pharmacoinvasive strategy only in patient with a
low to intermediate GRACE risk score (<155), while the
early invasive strategy was associated with worse outcome
in high-risk patients (≥155) [14]. The pharmacoinvasive
strategy was associated with a lower risk of death/re-MI in
the low-intermediate GRACE risk group (HR = 0.52, 95 %
CI 0.32–0.86, p = 0.010), but a higher risk of death/re-MI in
the GRACE high-risk group (HR = 1.98, 95 % CI 1.06–3.67,
p = 0.031) [14]. From this subgroup analysis from
TRANSFER-AMI, risk score may also guide the best
strategy to achieve and maintain myocardial reperfusion
after administration of fibrinolytic therapy [14]. Similar to
our study, the longer delay pharmacoinvasive strategy (24 h
to 2 weeks after successful fibrinolysis) in non PCI-capable
facilities may associate with the worst of composite
cardiovascular outcome (death, re-hospitalized with ACS,
re-hospitalized with HF and stroke) at 30-day and 6-month
when compared with the patients with low GRACE score
(15.6 % vs 2.3 % at 30 days, p = 0.003 and 16.7 % vs 6.8 % at
6 months, p = 0.024). Therefore, the patients with
intermediate to high GRACE risk score should be early
transferred to PCI-capable center after fibrinolytic therapy.
The in-hospital mortality and 6-month mortality of
our study was lower than the previous registry (TRACS)
because the difference in baseline patient characteristics,
the severity of the patients and the number of the
Table 4 Clinical outcomes at 1 and 6 months of follow-up (n= 152)
Clinical outcomes Low GRACE
group (N = 88)
Intermediate to high
GRACE group (N = 64)
P-value
In-hospital mortality, n (%) 0 (0) 2 (3.1) 0.095
At 1 month
Composite outcomes 2 (2.3) 10 (15.6) 0.003
ACS 1 (1.1) 1 (1.6) 0.666
Heart failure 1 (1.1) 6 (9.4) 0.022
Stroke 0 (0) 1 (1.6) 0.421
CV death 0 (0) 2 (3.1) 0.180
Non-CV death 0 (0) 0 (0) NS
Loss to follow-up 2 (2.3) 2 (3.1) 0.562
At 6 month (cumulative)
Composite outcomes 6 (6.8) 12 (18.7) 0.024
ACS 4 (4.5) 1 (1.6) 0.298
Heart failure 2 (2.3) 7 (10.9) 0.036
Stroke 0 (0) 2 (3.1) 0.421
CV death 0 (0) 2 (3.1) 0.175
Non-CV death 0 (0) 0(0) NS
Loss to follow-up 2 (2.3) 2 (3.1) 0.562
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patients received of the percutaneous coronary
intervention on admission (in-hospital mortality 5.3 % vs
3.1 % and 6-month mortality 12.1 % vs 3.1 %) [6]. Most
of the patients in our study had multivessel disease but
underwent culprit vessel PCI only in significant
proportion of patients. A small number of the patients
underwent multivessel PCI during index hospitalization
(10.7 % in low GRACE group vs 7.7 % in intermediate to
high GRACE group). The meta-analysis and systematic
review of Moretti et al. [22] in management multivessel
coronary disease in STEMI patients, 5855 patients from
6 studies (1 RCT) compared between only culprilt
vessel PCI vs complete PCI performed during index
hospitalization. No difference in major adverse cardio-
vascular events (MACE) at short-term (90 days) and
long term outcome at 1 year but significant reduced the
repeat revascularization at 1 year similar to culprit
vessel PCI vs complete revascularization during PCI.
The rate of CABG was high especially in intermediate
to high GRACE group because of high prevalence of
multivessel disease and complex coronary artery disease
(Type B2 and C) which may suitable for CABG after
acute phase of STEMI. Previous ACS registry in
Thailand (TRACS) showed the lower rate of CABG but
the revascularization data was collected only in
hospital-phase of STEMI [6]. The selective biased in
enrolled patients who survived during index admission
may contribute to low cardiovascular event in our
study. We showed the performance of GRACE score
for mortality of in-hospital, short term (30 days) and
6-month Therefore, the GRACE risk score is useful for
prediction in short- and long-term mortality of the
STEMI patients with successful fibrinolysis and delay
intervention in non PCI-capable hospital.
There are some limitations in our study that may
compromise clinical implication. Our study was a
retrospective observational study (non-randomized). The
large number of excluded patients reflected the limited
Number patients at risk 0 day 30 days 180 days
Low GRACE group 88 86 82
Intermediate to high GRACE group 64 54 52
P=0.022
Fig. 2 Kaplan-Meier of composite cardiovascular outcome
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accessibility to coronary intervention within 2 weeks.
The mortality was lower than the previous study because
the small number of patients with high GRACE risk
were included in our study.
Conclusion
The long delay pharmacoinvasive strategy in intermedi-
ate to high GRACE score after successful fibrinolysis in
non PCI-capable facilities were associated with worse
cardiovascular outcomes (death, re-hospitalized with
ACS, re-hospitalized with HF and stroke) than the
patients with low GRACE score at 30 days and
6 months. GRACE risk score may be helpful and guided
the clinicians in non PCI-capable center in early









0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.7945 (95% CI 0.75-0.83)






0.00 0.25 0.50 0.75 1.00
1 - Specificity
Area under ROC curve = 0.6410 (95% CI 0.52-0.76)
ROC curve of composite cardiovascular outcome
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Additional file
Additional file 1: Prognostic value of GRACE. The dataset for the
prognostic value of GRACE risk score analysis. (XLSX 52 kb)
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myocardial infarction
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